Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
NasdaqCM - Delayed Quote USD

Cadrenal Therapeutics, Inc. (CVKD)

Compare
17.40
-1.60
(-8.42%)
At close: March 3 at 4:00:02 PM EST
17.00
-0.40
(-2.30%)
After hours: March 3 at 6:19:17 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Quang X. Pham Chairman & CEO 967k -- 1965
Mr. Matthew K. Szot CPA, CPA Co-Founder & CFO 594.89k -- 1974
Mr. Jeffrey Cole Chief Operating Officer -- -- --
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer -- -- 1955

Cadrenal Therapeutics, Inc.

822 A1A North
Suite 306
Ponte Vedra, FL 32082
United States
904 300 0701 https://www.cadrenal.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Corporate Governance

Cadrenal Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

February 7, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 3, 2025 at 12:00 AM UTC

S-8: Offering Registrations

November 21, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

November 14, 2024 at 12:00 AM UTC

D: Additional Forms

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 24, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 20, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

ICU SeaStar Medical Holding Corporation
1.7700
+2.31%
 
STRO Sutro Biopharma, Inc.
1.4350
-9.75%
 
ZVSA ZyVersa Therapeutics, Inc.
1.0500
-7.08%
 
STTK Shattuck Labs, Inc.
1.2200
-7.58%
 
MAIA MAIA Biotechnology, Inc.
1.7000
-9.57%
 
IKT Inhibikase Therapeutics, Inc.
2.2700
-1.30%
 
SCPH scPharmaceuticals Inc.
3.2100
-2.13%
 
ACRV Acrivon Therapeutics, Inc.
5.14
-3.20%
 
CGON CG Oncology, Inc.
25.10
-2.94%
 
PTIX Protagenic Therapeutics, Inc.
0.2763
-9.41%